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creativecommons.org/licenses/by-nc-nd/Abstract Symptomatic skeletal events (SSEs) commonly occur in patients with bone metas-
tases, often leading to hospitalisations and decreased quality-of-life. In the ALSYMPCA trial,
radium-223 significantly improved overall survival (hazard ratio 0.70, 95% confidence interval
[CI] 0.58e0.83, P < 0.001) and prolonged time to first SSE (hazard ratio 0.66, 95% CI 0.52
e0.83, P Z 0.00037) and subsequent SSE (hazard ratio 0.65, 95% CI 0.51e0.83,
P Z 0.00039) versus placebo in patients with castration-resistant prostate cancer with symp-
tomatic bone metastases and no known visceral metastases. Health care resource use (HCRU),
including hospitalisation events and days, were prospectively collected in ALSYMPCA. We
assessed health care resource use for the first 12 months post-randomisation. Significantly
fewer radium-223 (218/589; 37.0%) versus placebo patients (133/292; 45.5%) had at least
one hospitalisation event (P Z 0.016). However, mean number of hospitalisation events per
patient was similar (radium-223 0.69 versus placebo 0.79, PZ 0.226), likely due to the signif-
icantly longer follow-up time for radium-223 (7.82 months versus 6.92 months for placebo;hs.uk (C. Parker).
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C. Parker et al. / European Journal of Cancer 71 (2017) 1e62P < 0.001). There were significantly fewer hospitalisation days per patient for radium-223
(4.44 versus 6.68, respectively, P Z 0.004). The reduction in hospitalisation days with
radium-223 was observed both before first SSE (2.35 days versus 3.36 days, respectively)
and after SSE (7.74 days versus 9.19 days, respectively). Our data suggest that this reduced
hospital days along with the survival benefit and reduction in time to SSEs with radium-
223 treatment may contribute to improvements in health-related quality-of-life in patients with
castration-resistant prostate cancer with symptomatic bone metastases (ALSYMPCA Clini-
calTrials.gov number, NCT00699751.).
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Skeletal-related events (SREs) commonly occur in pa-
tients with bonemetastases and prostate cancer [1e5] and
are associated with increased morbidity (including sig-
nificant pain) and mortality [1,3,5,6] and decreased
quality-of-life (QoL) [3,6]. In addition, SREs are associ-
ated with increased health care resource use (HCRU)
[1,3,6] and costs [1,7,8]. Patients with prostate cancer and
bone metastases and 1 SRE have a 2-fold increase in
emergency department visits and a 4-fold increase in
hospitalisations versus those without SREs [1], and costs
are substantially higher, especially when SRE treatment
requires concurrent surgery [8]. Considering the
increased burden of metastatic castration-resistant pros-
tate cancer (mCRPC), there is a need for effective ther-
apies targeted at bone metastases for the prevention and
management of SREs and improving patient outcomes.
The ALSYMPCA trial results demonstrated that
radium-223 versus placebo improves overall survival
and prolongs time to first and subsequent symptomatic
skeletal events (SSEs) in patients with bone metastases
from CRPC [9,10]. In this post-hoc analysis from
ALSYMPCA, we evaluated the effect of radium-223 on
HCRU, including hospitalisation days before first SSE
and after SSE, over the first 12 months following
treatment randomisation.2. Methods
The ALSYMPCA study design (phase 3, randomised,
double-blind, placebo-controlled) and patient enrolment
criteria have been published [9]. Briefly, patients with
CRPC with symptomatic bone metastases and no
known visceral metastases were randomly allocated in a
2:1 ratio to receive radium-223 plus best standard of
care or placebo plus best standard of care. Radium-223/
matching placebo treatments were administered at 4-
week intervals for a total of 6 injections. The study
protocol was approved by the institutional review
boards at each participating study center, and all pa-
tients provided written informed consent.
In the current analysis, we evaluated the effect of
radium-223 on HCRU over the first 12 months followingtreatment randomisation. The first 12 months following
treatment initiation with radium-223 is considered the
most clinically meaningful and reflective of treatment
effect on HCRU during which most patients would be
evaluable and most HCRU would be used [11]. Hospi-
talisation event rate within a treatment group was
calculated as the number of patients with at least one
hospitalisation event divided by the total number of pa-
tients; a Fisher’s exact test was used for treatment group
comparison. The following HCRU outcomes were pro-
spectively collected at each study visit from random-
isation through week 52 and totalled by category for each
patient: hospitalisation events (in-patient admissions),
hospitalisation days, physician visits, nursing home stays,
home health care hours, and adult day care visits. Means
and standard deviations were reported for each HCRU
category, and non-annualised resource use between
treatments was compared via t-tests. The analysis popu-
lation included only patients from the intention-to-treat
population (i.e. all randomised patients) who had
HCRU data available. All analyses were conducted using
SAS 9.4 software (SAS Institute Inc).
The further analysis of hospitalisation days compared
treatment differences before first SSE and after SSE. An
SSE was defined as use of external-beam radiation
therapy to relieve bone pain, new symptomatic patho-
logic vertebral or non-vertebral bone fractures, spinal
cord compression, or tumour-related orthopaedic sur-
gical intervention. All events had to be clinically
apparent. The pre-SSE population included all patients
with observations before first SSE, and post-SSE
included all patients with observations after SSE. Pa-
tients with a known history of SSE before study entry or
before first study treatment were not included in the pre-
SSE population but were included in the post-SSE
population.3. Results
A total of 921 patients were randomised in
ALSYMPCA, 614 to radium-223 and 307 to
placebo and 20 (15 radium-223, 5 placebo) patients
withdrew without receiving study drug. Of the remain-
ing 901 patients, 599 radium-223 patients and 302
Table 1
Primary reasons for hospitalisation.a
Reason for hospitalisation Radium-223
N Z 589
Placebo
N Z 292
At least 1 hospitalisation, n (%) 218 (37.0%) 133 (45.5%)
P-value for difference between
treatments
P Z 0.016
Radium-223 Placebo
Total number (no.) of hospitalisations 423 237
No. of hospitalisations
with a listed reasonb
420 230
Bone pain, no. of hospitalisations (%) 42 (10.0%) 31 (13.5%)
Pain, no. of hospitalisations (%) 39 (9.3%) 12 (5.2%)
Anaemia, no. of hospitalisations (%) 36 (8.6%) 22 (9.6%)
Infection, no. of hospitalisations (%) 32 (7.6%) 13 (5.7%)
Blood transfusion, no. of
hospitalisations (%)
14 (3.3%) 5 (2.2%)
Spinal cord compression, no.
of hospitalisations (%)
9 (2.1%) 10 (4.3%)
a Five most common reasons in each group; the 6th reason in each
group is listed for purposes of table balance (i.e. spinal cord
compression in the radium-223 group and blood transfusion in the
placebo group).
b For 3 hospitalisations in the radium-223 group and for 7 in the
placebo group, the reason for hospitalisation was not listed.
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mographic and clinical characteristics, including
bisphosphonate use, were well balanced between the
radium-223 and placebo groups [9]. A total of 41% of
the patients in the radium-223 group and 40% of the
patients in the placebo group reported bisphosphonate
use at baseline [9]. For each HCRU category, data were
available for 578e589 radium-223 patients and 287e292
placebo patients (details in Fig. 1).
Significantly fewer radium-223 patients (218/589;
37.0%) than placebo patients (133/292; 45.5%) had at
least one hospitalisation event (two-sided P-
valueZ 0.016). The primary reasons for hospitalisation
are listed in Table 1. Among patients with data on
hospitalisation, the mean follow-up time was 7.82
months for radium-223 and 6.92 months for placebo
(P < 0.001). The mean number of hospitalisation events
per patient was similar for radium-223 and placebo (0.69
versus 0.79, respectively; 95% confidence interval for
difference in means [0.27, 0.06]; P Z 0.226; Table 2).
In contrast, treatment with radium-223 significantly
reduced mean hospitalisation days per patient versus
placebo (4.44 versus 6.68, respectively; 95% confidence
interval for difference in means [3.77, 0.72]; PZ 0.004;
Fig. 2A).
As shown in Table 2, there were no statistical dif-
ferences between treatments for the other HCRU cate-
gories analysed.3.1. Hospitalisation days according to SSE occurrence
Of the 874 (586 radium-223, 288 placebo) patients with
data on hospitalisation days (Fig. 1), 27 (16 radium-223Fig. 1. Patients evaluable for the heand 11 placebo) patients had known SSE before study
entry/before first study treatment and therefore were
excluded from the pre-SSE analysis population. These
27 patients, however, were among the 271 patients in the
post-SSE population. The mean follow-up times were
6.7 months for radium-223 and 5.4 months for placebo
before first SSE, and 4.6 and 4.5 months, respectively,
after SSE. Hospitalisation days per patient increased in
both treatment arms following SSE from 2.35 to 7.74
days for radium-223 and from 3.36 to 9.19 days foralth care resource use analysis.
Table 2
Health care resource use for first 12 months following treatment randomisation (ITT population).
Health care resource use Radium-223
N Z 614
Placebo
N Z 307
Treatment difference (SD) P-value
Hospitalisation events (SD) 0.69 (1.20) 0.79 (1.15) 0.10 (1.19) 0.226
Hospitalisation days (SD) 4.44 (10.05) 6.68 (12.12) 2.24 (10.78) 0.004
Physician visits (SD) 4.25 (6.97) 4.24 (6.63) 0.01 (6.86) 0.980
Nursing home weeks (SD) 0.12 (0.98) 0.22 (1.84) 0.10 (1.33) 0.292
Adult day care days (SD) 0.42 (3.17) 0.38 (3.49) 0.04 (3.28) 0.876
Home health care hours (SD) 7.59 (57.64) 4.12 (19.52) 3.48 (48.45) 0.321
Data are means (standard deviation, SD); p-values are from a t-test comparing treatment differences and may represent biased comparisons due to
differences in observation times.
Data on hospitalisation events, hospitalisation days, physician visits, nursing home weeks, adult day care days, and home health care hours were
available for 587, 586, 584, 589, 584, 578 patients, respectively, in the radium-223 arm and for 292, 288, 290, 292, 290, 287 patients, respectively, in
the placebo arm.
ITT Z intention-to-treat.
Fig. 2. Mean hospitalisation days per patient for the first 12 months following treatment randomisation. Treatment differences (SD) are
also shown. (A) All patients evaluable for hospitalisation days. (B) Patients evaluable for hospitalisation days before first SSE and after
SSE (by definition, the pre-SSE population included all patients with observations before first SSE, and post-SSE included all patients with
observations after SSE). SD, standard deviation; SSE, symptomatic skeletal event.
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radium-223 was associated with fewer hospitalisation
days per patient before first SSE and after SSE (Fig. 2B).
4. Discussion
The present analysis evaluated HCRU over the first 12
months following treatment randomisation to either
radium-223 or placebo. Significantly fewer patients
treated with radium-223 versus placebo had at least one
hospitalisation event (37.0% versus 45.5%, P Z 0.016).
Overall, radium-223 patients experienced a 12.7%
reduction in hospitalisation events per patient
(PZ 0.226) and a 33% reduction in hospitalisation days
per patient (P Z 0.004). These results may possibly be
explained by the delayed time to first SSE and the
overall reduced number of SSEs with radium-223
treatment [10].Skeletal-related events result in increased HCRU,
and hospitalisation due to SREs occurs in up to 82% of
patients with prostate cancer and bone metastases, with
frequency dependent on the type of SRE [3,4,7,8]. A
reduction in skeletal morbidity has important cost
consequences. Average HCRU costs are about $30,000
higher in patients with SREs versus without SREs, with
64% being inpatient costs [8]. Considering the benefits of
radium-223 on SSEs and the influence of skeletal com-
plications on HCRU, we further explored the impact of
radium-223 on hospitalisation days before first SSE and
after SSE to determine whether the reduction in hospi-
talisation duration remains the same.
Spinal cord compression, an SSE commonly
requiring hospitalisation, has been associated with the
longest duration of stay [3]. In ALSYMPCA, the risk
for spinal cord compression was significantly reduced
with radium-223 (P Z 0.03) [10]. Considering SSEs
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than placebo patients (33% versus 38%, respectively)
and median time to first SSE (15.6 months versus 9.8
months) and subsequent SSE (w16.5 months
versus 10.1 months) were significantly (P < 0.0004)
longer for radium-223 [10]. The present analysis con-
firms the influence of SSEs and radium-223 on HCRU.
Radium-223 versus placebo was associated with fewer
hospitalisation days pre-SSE and post-SSE
versus placebo (Fig. 2B). The decrease in hospital-
isation days pre-SSE indicates an effect beyond delaying
SSE, which could be related to the reduced need for pain
management. Time to external beam radiation therapy
and time to initial opioid use were significantly longer
with radium-223 (P Z 0.001 and P Z 0.002, respec-
tively) [12]. The decrease in hospitalisation days post-
SSE may possibly be explained by a delay or avoid-
ance of subsequent SSE [10].
Length of hospital stay has been reported to increase
as prostate cancer progresses to include bone metastases
and SREs [6]. Likewise, we found that hospitalisation
days (duration) increased after SSE in both treatment
arms (Fig. 2B). Moreover, previous analyses have
shown that radium-223 provides more meaningful im-
provements in QoL versus placebo, and that the QoL
treatment benefits are greater before the occurrence of
SSE [9,13,14]. These findings suggest the importance of
radium-223 treatment before an SSE arises.
In our analysis, differences in hospital-related HCRU
favoured radium-223 and were statistically significant
versus placebo for mean number of hospitalisation days
per patient and percentage of patients with at least one
hospitalisation event. However, while treatment with
radium-223 resulted in fewer mean number of hospital-
isation events per patient, the difference compared to
placebo was not statistically significant. This is likely due
to the significantly longer follow-up time for radium-223
patients (7.82 months versus 6.92 months for placebo
patients, P < 0.001), which was not accounted for in our
analyses and could have minimised the observed treat-
ment differences, leading to potential bias against
radium-223. Both the radium-223 and placebo groups
had similar rates of bisphosphonate use at baseline, and
we did not examine HCRU based on this parameter.
However, considering that overall survival was not
influenced by bisphosphonate use in the primary analysis
data set [9], we would not expect bisphosphonate use to
have an influence on HCRU outcomes.5. Conclusion
Radium-223 improves overall survival and reduces the
risk for SSEs in men with CRPC and bone metastases.
The benefits of radium-223 are further extended by a
reduction in hospitalisation days, as observed before
first SSE and after SSE. Together these data suggest thatuse of radium-223 may contribute to reduced HCRU,
including reduced hospitalisation days possibly through
delayed time to first and subsequent SSE, and im-
provements in health-related QoL.
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